PharmGen Science, Inc.

KOSE:A004720 Stock Report

Market Cap: ₩70.3b

PharmGen Science Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for PharmGen Science.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth21.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Mar 30

Some Investors May Be Willing To Look Past PharmGen Science's (KRX:004720) Soft Earnings

Shareholders appeared unconcerned with PharmGen Science, Inc.'s ( KRX:004720 ) lackluster earnings report last week. We...
Analysis Article • Aug 12

PharmGen Science, Inc.'s (KRX:004720) Share Price Could Signal Some Risk

When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") below 11x, you may consider...
Analysis Article • Mar 27

PharmGen Science's (KRX:004720) Shareholders Have More To Worry About Than Only Soft Earnings

The subdued market reaction suggests that PharmGen Science, Inc.'s ( KRX:004720 ) recent earnings didn't contain any...
Analysis Article • Mar 21

Is Wooridul Pharmaceutical (KRX:004720) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Jan 19

Investors Who Bought Wooridul Pharmaceutical (KRX:004720) Shares Five Years Ago Are Now Up 55%

While Wooridul Pharmaceutical Limited ( KRX:004720 ) shareholders are probably generally happy, the stock hasn't had...
Analysis Article • Dec 21

Does The Market Have A Low Tolerance For Wooridul Pharmaceutical Limited's (KRX:004720) Mixed Fundamentals?

It is hard to get excited after looking at Wooridul Pharmaceutical's (KRX:004720) recent performance, when its stock...
Analysis Article • Nov 25

Are Wooridul Pharmaceutical's (KRX:004720) Statutory Earnings A Good Reflection Of Its Earnings Potential?

As a general rule, we think profitable companies are less risky than companies that lose money. However, sometimes...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PharmGen Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSE:A004720 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2025171,658118-3,743-1,287N/A
12/31/2024171,2872,791-3992,384N/A
9/30/2024173,599-8745923,343N/A
6/30/2024173,0959176132,811N/A
3/31/2024171,6876,5713,1156,258N/A
12/31/2023166,7796,0892,1875,439N/A
9/30/2023159,1484,771-5,1454,193N/A
6/30/2023154,3057,750-7,4282,980N/A
3/31/2023147,56013,583-12,090-691N/A
12/31/2022150,93170,060-13,242-1,286N/A
9/30/2022144,55084,614-9,300-1,204N/A
6/30/2022135,54387,508-6,8312,794N/A
3/31/2022126,82168,050-20,3344,904N/A
12/31/2021109,86632,466-26,2267,784N/A
9/30/2021103,48025,484-27,5084,324N/A
6/30/202199,84624,220-27,4693,125N/A
3/31/202197,66332,720-9,1643,221N/A
12/31/202096,6149,222-2,2462,676N/A
9/30/202094,2872,202-3,8204,490N/A
6/30/202093,162-432-5,3472,487N/A
3/31/202094,875-1,355-5,6943,272N/A
12/31/201995,138302-4,2592,523N/A
9/30/201994,2142,3231,8525,191N/A
6/30/201994,1982,7123,3525,560N/A
3/31/201990,9234,0761,1062,370N/A
12/31/201889,1024,468N/A4,216N/A
9/30/201887,8033,989N/A81N/A
6/30/201885,4135,267N/A2,602N/A
3/31/201882,1274,510N/A4,958N/A
12/31/201779,8944,320N/A1,838N/A
9/30/201775,4174,869N/A3,308N/A
6/30/201773,4873,811N/A2,377N/A
3/31/201771,9942,638N/A4,168N/A
12/31/201671,5463,452N/A7,755N/A
9/30/201671,5312,087N/A7,161N/A
6/30/201667,757369N/A6,064N/A
3/31/201664,7352,202N/A4,603N/A
12/31/201560,4052,067N/A3,622N/A
9/30/201554,461-459N/A1,617N/A
6/30/201551,294-202N/A-514N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A004720's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A004720's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A004720's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A004720's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A004720's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A004720's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 07:39
End of Day Share Price 2026/06/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmGen Science, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.